Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
sledai 2k score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • No Activity0–2
  • Mild Activity3–4
  • Moderate Activity5–10
  • High Activity11–19
Direct Clinical Answer

The Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) calculates classifying inflammatory arthritides and monitoring longitudinal autoimmune disease activity. Key inputs include seizure. Scores guide initiating or optimizing disease-modifying antirheumatic drugs (DMARDs) or targeted biologic therapies. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Stratifies severity of systemic lupus erythematosus (SLE) based on 24 clinical and laboratory parameters, allowing documentation of persistent disease activity.

Clinical Indication

The Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) is indicated for bedside clinical practice to support Stratifies severity of systemic lupus erythematosus (SLE) based on 24 clinical and laboratory parameters, allowing documentation of persistent disease activity.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with inflammatory arthritis, systemic lupus erythematosus, systemic vasculitis, or autoimmune connective tissue disorders. Clinical application is indicated across Rheumatology clinics, connective tissue disease units, and academic medical centers.

Limitations & Contraindications

Elevated erythrocyte sedimentation rate (ESR) and CRP are non-specific acute phase reactants that can reflect occult systemic infection.

Clinical Pearls & Action Plan

Serological autoantibody testing must strictly correlate with inflammatory joint patterns and objective synovial pathology.

Formula & Variables:

Sum of weighted scores for 24 items (8 points for CNS/vascular, 4 points for renal/musculoskeletal, 2 points for serositis/dermatologic/immunologic, 1 point for constitutional/hematologic)

Input Parameters

NameTypeRequiredDescription
seizurestringYesRecent onset seizure (exclude metabolic, infectious, or drug causes)
psychosisstringYesAltered mental function with impaired reality perception (exclude uremia, drugs)
organic_brain_syndromestringYesAltered mental function with impaired cognition, memory, or concentration
visual_disturbancestringYesRetinal changes of SLE (cytoid bodies, retinal hemorrhages, exudates, hemorrhage in choroid or optic neuritis)
cranial_nerve_disorderstringYesNew onset sensory or motor neuropathy involving cranial nerves
lupus_headachestringYesSevere persistent headache, may be migrainous, nonresponsive to narcotic analgesia
cvastringYesNew onset cerebrovascular accident (stroke)
vasculitisstringYesUlceration, gangrene, tender finger nodules, periungual infarction, splinter hemorrhages, or biopsy/angiogram proof
arthritisstringYes≥2 joints with pain and signs of inflammation (tenderness, swelling, or effusion)
myositisstringYesProximal muscle aching/weakness with elevated CPK/aldolase or EMG changes or biopsy showing myositis
urinary_castsstringYesHeme-granular or red blood cell casts
hematuriastringYes>5 RBCs/high power field (exclude stone, infection, or other causes)
proteinuriastringYesNew onset or recent increase >0.5 g/24 hours
pyuriastringYes>5 WBCs/high power field (exclude infection)
rashstringYesNew or ongoing inflammatory type rash
alopeciastringYesNew or ongoing abnormal patchy or diffuse hair loss
mucosal_ulcersstringYesNew or ongoing oral or nasal ulcerations
pleurisystringYesPleuritic chest pain with pleural rub, effusion, or pleural thickening
pericarditisstringYesPericardial pain with rub, effusion, or ECG/echo confirmation
low_complementstringYesDecreased C3, C4, or CH50 below normal lab limits
increased_dna_bindingstringYesIncreased anti-dsDNA antibody binding above normal range
feverstringYesTemperature >100.4°F (38°C) excluding infection
thrombocytopeniastringYesPlatelets <100 × 10⁹/L excluding drug causes
leukopeniastringYesWBC <3 × 10⁹/L excluding drug causes

Score Interpretation & Guidance

RangeStageDescription
0–2No ActivityNo disease activity
3–4Mild ActivityMild disease activity
5–10Moderate ActivityModerate disease activity
11–19High ActivityHigh disease activity
20–105Very High ActivityVery high disease activity

Evidence-Based References (EBM)

  • Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288-91.
  • Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005 Jun 21;142(12 Pt 1):953-62.
  • Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus. 2010 Jan;19(1):49-51. doi: 10.1177/0961203309346505.DOI: 10.1177/0961203309346505

Related calculators